[日本語] English
万見文献
- EMDB/PDB/SASBDBから引用されている文献のデータベース -

+
検索条件

キーワード
構造解析手法
著者・登録者
ジャーナル
IF

-
Structure paper

タイトルMining the PDB for Tractable Cases Where X-ray Crystallography Combined with Fragment Screens Can Be Used to Systematically Design Protein-Protein Inhibitors: Two Test Cases Illustrated by IL1 beta-IL1R and p38 alpha-TAB1 Complexes.
ジャーナル・号・ページJ. Med. Chem., Vol. 63, Page 7559-7568, Year 2020
掲載日2020年3月3日 (構造データの登録日)
著者Nichols, C. / Ng, J. / Keshu, A. / Kelly, G. / Conte, M.R. / Marber, M.S. / Fraternali, F. / De Nicola, G.F.
リンクJ. Med. Chem. / PubMed:32543856
手法X線回折
解像度1.22 - 1.986 Å
構造データ

PDB-5r85:
PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z1262246195 in complex with INTERLEUKIN-1 BETA
手法: X-RAY DIFFRACTION / 解像度: 1.44 Å

PDB-5r86:
PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z943693514 in complex with INTERLEUKIN-1 BETA
手法: X-RAY DIFFRACTION / 解像度: 1.5 Å

PDB-5r87:
PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z44592329 in complex with INTERLEUKIN-1 BETA
手法: X-RAY DIFFRACTION / 解像度: 1.47 Å

PDB-5r88:
PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z1545313172 in complex with INTERLEUKIN-1 BETA
手法: X-RAY DIFFRACTION / 解像度: 1.48 Å

PDB-5r89:
PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z217038356 in complex with INTERLEUKIN-1 BETA
手法: X-RAY DIFFRACTION / 解像度: 1.65 Å

PDB-5r8a:
PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z1492796719 in complex with INTERLEUKIN-1 BETA
手法: X-RAY DIFFRACTION / 解像度: 1.47 Å

PDB-5r8b:
PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z2027049478 in complex with INTERLEUKIN-1 BETA
手法: X-RAY DIFFRACTION / 解像度: 1.49 Å

PDB-5r8c:
PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z30857828 in complex with INTERLEUKIN-1 BETA
手法: X-RAY DIFFRACTION / 解像度: 1.54 Å

PDB-5r8d:
PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z1745658474 in complex with INTERLEUKIN-1 BETA
手法: X-RAY DIFFRACTION / 解像度: 1.47 Å

PDB-5r8e:
PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z57475877 in complex with INTERLEUKIN-1 BETA
手法: X-RAY DIFFRACTION / 解像度: 1.35 Å

PDB-5r8f:
PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z2377835233 in complex with INTERLEUKIN-1 BETA
手法: X-RAY DIFFRACTION / 解像度: 1.41 Å

PDB-5r8g:
PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z1259086950 in complex with INTERLEUKIN-1 BETA
手法: X-RAY DIFFRACTION / 解像度: 1.43 Å

PDB-5r8h:
PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z111716368 in complex with INTERLEUKIN-1 BETA
手法: X-RAY DIFFRACTION / 解像度: 1.5 Å

PDB-5r8i:
PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z210803634 in complex with INTERLEUKIN-1 BETA
手法: X-RAY DIFFRACTION / 解像度: 1.47 Å

PDB-5r8j:
PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z355728146 in complex with INTERLEUKIN-1 BETA
手法: X-RAY DIFFRACTION / 解像度: 1.62 Å

PDB-5r8k:
PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z355728146 in complex with INTERLEUKIN-1 BETA
手法: X-RAY DIFFRACTION / 解像度: 1.47 Å

PDB-5r8l:
PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z1891773393 in complex with INTERLEUKIN-1 BETA
手法: X-RAY DIFFRACTION / 解像度: 1.56 Å

PDB-5r8m:
PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z1818332938 in complex with INTERLEUKIN-1 BETA
手法: X-RAY DIFFRACTION / 解像度: 1.39 Å

PDB-5r8n:
PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z57292400 in complex with INTERLEUKIN-1 BETA
手法: X-RAY DIFFRACTION / 解像度: 1.48 Å

PDB-5r8o:
PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z1881545321 in complex with INTERLEUKIN-1 BETA
手法: X-RAY DIFFRACTION / 解像度: 1.42 Å

PDB-5r8p:
PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z818727262 in complex with INTERLEUKIN-1 BETA
手法: X-RAY DIFFRACTION / 解像度: 1.53 Å

PDB-5r8q:
PanDDA analysis group deposition INTERLEUKIN-1 BETA -- Fragment Z2643472210 in complex with INTERLEUKIN-1 BETA
手法: X-RAY DIFFRACTION / 解像度: 1.23 Å

PDB-5r8u:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N05703b in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.48 Å

PDB-5r8v:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N09139b in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.479 Å

PDB-5r8w:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment K00283c in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.5 Å

PDB-5r8x:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N11396a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.73 Å

PDB-5r8y:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N08078b in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.679 Å

PDB-5r8z:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N01381c in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.65 Å

PDB-5r90:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N11145a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.619 Å

PDB-5r91:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment KCL057 in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.731 Å

PDB-5r92:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment KCL063 in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.66 Å

PDB-5r93:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment KCL077 in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.489 Å

PDB-5r94:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment KCL081 in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.45 Å

PDB-5r95:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment KCL093 in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.59 Å

PDB-5r96:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment KCL095 in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.767 Å

PDB-5r97:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13662a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.438 Å

PDB-5r98:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N14109a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.68 Å

PDB-5r99:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13619a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.89 Å

PDB-5r9a:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13838a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.53 Å

PDB-5r9b:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13866a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.657 Å

PDB-5r9c:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N14074a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.74 Å

PDB-5r9d:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment S00888c in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.69 Å

PDB-5r9e:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13693a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.775 Å

PDB-5r9f:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13724a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.986 Å

PDB-5r9g:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment PC587 in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.73 Å

PDB-5r9h:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment TCJ658 in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.49 Å

PDB-5r9i:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment TCJ795 in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.813 Å

PDB-5r9j:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N14231a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.52 Å

PDB-5r9k:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N14246a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.498 Å

PDB-5r9l:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N14274a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.47 Å

PDB-5r9m:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13418a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.809 Å

PDB-5r9n:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13421a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.688 Å

PDB-5r9o:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N06122b in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.6 Å

PDB-5r9p:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13430a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.72 Å

PDB-5r9q:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N07422b in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.645 Å

PDB-5r9r:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13413a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.76 Å

PDB-5r9s:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13470a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.7 Å

PDB-5r9t:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13477a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.8 Å

PDB-5r9u:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13475a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.67 Å

PDB-5r9v:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13596a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.45 Å

PDB-5r9w:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13598a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.89 Å

PDB-5r9x:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13611a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.72 Å

PDB-5r9y:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13619a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.57 Å

PDB-5r9z:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13502a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.66 Å

PDB-5ra0:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N13421a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.91 Å

PDB-5ra1:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N08141b in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.61 Å

PDB-5ra2:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N09036b in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.57 Å

PDB-5ra3:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N10836b in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.57 Å

PDB-5ra4:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N11337a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.59 Å

PDB-5ra5:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N11302a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.54 Å

PDB-5ra6:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N11338a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.86 Å

PDB-5ra7:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N11351a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.92 Å

PDB-5ra8:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N05711b in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.78 Å

PDB-5ra9:
PanDDA analysis group deposition Form1 MAP kinase p38-alpha -- Fragment N08051b in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.68 Å

PDB-6so1:
Fragment N13569a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.66 Å

PDB-6so2:
Fragment N13460a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.6 Å

PDB-6so4:
Fragment RZ132 in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.51 Å

PDB-6sod:
Fragment N14056a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.87 Å

PDB-6soi:
Fragment N13788a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.55 Å

PDB-6sot:
Fragment N11290a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.54 Å

PDB-6sou:
Fragment N13565a in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.5 Å

PDB-6sov:
Fragments KCL_615 and KCL_802 in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.31 Å

PDB-6sp9:
Fragment KCL802 in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.22 Å

PDB-6spl:
Fragment KCL615 in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.38 Å

PDB-6y7w:
Fragment KCL_1337 in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.39 Å

PDB-6y7x:
Fragment KCL_771 in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.45 Å

PDB-6y7y:
Fragments KCL_771 and KCL_802 in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.51 Å

PDB-6y80:
Fragment KCL_916 in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.24 Å

PDB-6y81:
Fragment KCL_1088 in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.54 Å

PDB-6ycu:
Fragment KCL_K777 in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.35 Å

PDB-6ycw:
Fragment KCL_K767 in complex with MAP kinase p38-alpha
手法: X-RAY DIFFRACTION / 解像度: 1.34 Å

化合物

ChemComp-SO4:
SULFATE ION / 硫酸ジアニオン

ChemComp-S7A:
3,3,3-tris(fluoranyl)-1-piperazin-1-yl-propan-1-one

ChemComp-HOH:
WATER

ChemComp-GT4:
~{N}-(4-hydroxyphenyl)-2-methoxy-ethanamide

ChemComp-K0G:
N-phenyl-N'-pyridin-3-ylurea / 1-(3-ピリジル)-3-フェニル尿素

ChemComp-LWA:
(2~{S})-~{N}-(4-aminocarbonylphenyl)oxolane-2-carboxamide

ChemComp-S7D:
1-[(2~{S})-2-methylmorpholin-4-yl]-2-pyrazol-1-yl-ethanone

ChemComp-S7G:
~{N}-[(3~{R})-1,2,3,4-tetrahydroquinolin-3-yl]ethanamide

ChemComp-K34:
5-(1,3-thiazol-2-yl)-1H-1,2,4-triazole

ChemComp-M25:
N-{2-[4-(AMINOSULFONYL)PHENYL]ETHYL}ACETAMIDE / DK-42

ChemComp-S7J:
2-(trifluoromethyl)pyrimidine-5-carboxamide

ChemComp-S7S:
~{N}-(2-ethyl-1,2,3,4-tetrazol-5-yl)butanamide

ChemComp-K3Y:
1-methyl-3-[(3R)-piperidin-3-yl]-1H-pyrazole-4-carboxamide

ChemComp-S7V:
[(2~{R})-4-(phenylmethyl)morpholin-2-yl]methanol / (2R)-4-ベンジル-2-(ヒドロキシメチル)モルホリン

ChemComp-T91:
N-[2-(1H-benzimidazol-2-yl)ethyl]-2,2-dimethylpropanamide

ChemComp-A7N:
(1~{R})-1-(4-ethoxyphenyl)ethanamine

ChemComp-S8D:
2-[(2~{R},5~{S})-2,5-dimethylmorpholin-4-yl]-~{N}-ethyl-ethanamide

ChemComp-NY4:
N-{4-[(1S)-1-aminoethyl]phenyl}cyclopropanecarboxamide

ChemComp-S8G:
1-[(3~{R})-3-azanylpiperidin-1-yl]-4,4,4-tris(fluoranyl)butan-1-one

ChemComp-S8J:
3-ethoxy-~{N}-(2-methyl-1,2,3,4-tetrazol-5-yl)benzamide

ChemComp-S8P:
5-methyl-~{N}-[[(2~{S})-oxolan-2-yl]methyl]-1,2-thiazole-3-carboxamide

ChemComp-S8V:
~{N}-[[(3~{S})-oxolan-3-yl]methyl]cyclopropanamine

ChemComp-JGY:
1-methyl-N-{[(2S)-oxolan-2-yl]methyl}-1H-pyrazole-3-carboxamide

ChemComp-SLS:
3,4-dihydro-2~{H}-chromene-6-carboxamide

ChemComp-CL:
Unknown entry / クロリド

ChemComp-DMS:
DIMETHYL SULFOXIDE / 2-チアプロパン2-オキシド / DMSO, 沈殿剤*YM

ChemComp-MG:
Unknown entry / マグネシウムジカチオン

ChemComp-SLV:
~{N}-(3-oxidanyl-4-propyl-phenyl)ethanamide

ChemComp-JND:
6-ethylthieno[2,3-d]pyrimidin-4(3H)-one / 6-エチル-3,4-ジヒドロチエノ[2,3-d]ピリミジン-4-オン

ChemComp-SLY:
(2-phenoxyphenyl)methanamine

ChemComp-SMV:
thiophene-2-carbothioamide / チオフェン-2-カルボチオアミド

ChemComp-SN4:
6-methoxypyridine-3-carbothioamide / 6-メトキシピリジン-3-カルボチオアミド

ChemComp-ACT:
ACETATE ION / 酢酸イオン

ChemComp-SNJ:
2,5-diphenyl-4~{H}-pyrazol-3-one / 1,3-ジフェニル-2-ピラゾリン-5-オン

ChemComp-SNV:
2-[4-(2-aminophenyl)piperazin-1-yl]ethanol

ChemComp-SO7:
(3~{S})-~{N}-methoxy-1-(4-methoxyphenyl)-~{N}-methyl-5-oxidanylidene-pyrrolidine-3-carboxamide

ChemComp-SOJ:
~{N}4-phenylbenzene-1,4-diamine / 4-アミノジフェニルアミン

ChemComp-SOV:
5-[2,5-bis(oxidanylidene)pyrrol-1-yl]-2-methyl-benzenecarbonitrile

ChemComp-SQ4:
1-(4-aminophenyl)pyrrole-2,5-dione / N-(4-アミノフェニル)マレインイミド

ChemComp-EDO:
1,2-ETHANEDIOL / エチレングリコ-ル

ChemComp-SQ7:
3-(4-chlorophenyl)imidazole-2,4-dione / 3-(4-クロロフェニル)-3H-イミダゾ-ル-2,4-ジオン

ChemComp-RUY:
4-(piperidin-1-yl)-1,2,5-oxadiazol-3-amine

ChemComp-SQG:
2-cyano-~{N}-[4-(trifluoromethyloxy)phenyl]ethanamide / N-[4-(トリフルオロメトキシ)フェニル]-2-シアノアセトアミド

ChemComp-SU7:
3-oxidanylidene-3-[4-(phenylmethyl)piperidin-1-yl]propanenitrile / 3-(4-ベンジルピペリジノ)-3-オキソプロピオニトリル

ChemComp-SQM:
4-benzamido-2-methyl-pyrazole-3-carboxamide

ChemComp-GOL:
GLYCEROL / グリセロ-ル

ChemComp-JGM:
{N}-[(2~{S})-1-diazanyl-3-(4-hydroxyphenyl)-1-oxidanylidene-propan-2-yl]ethanamide

ChemComp-7ZC:
1-(5-methoxy-1H-indol-3-yl)-N,N-dimethyl-methanamine / 5-メトキシグラミン

ChemComp-N9J:
benzyl hydroxycarbamate / ヒドロキシカルバミド酸ベンジル

ChemComp-SQP:
2-(4-aminophenyl)benzoic acid / 4′-アミノ-1,1′-ビフェニル-2-カルボン酸

ChemComp-RGY:
(4R,4aS,7aS,9S)-3,10-dimethyl-5,6,7,7a,8,9-hexahydro-4H-4a,9-epiminopyrrolo[3',4':5,6]cyclohepta[1,2-d][1,2]oxazol-4-ol

ChemComp-SQV:
methyl (2~{S})-2-(4-methoxypyridin-2-yl)propanoate

ChemComp-SQY:
methyl (2~{R})-3-(4-bromophenyl)-2-pyridin-4-yl-propanoate

ChemComp-LXS:
3-ethyl-1-[(1~{R},8~{S},9~{S},10~{S})-10-oxidanyl-11-oxatricyclo[6.2.1.0^{2,7}]undeca-2(7),3,5-trien-9-yl]imidazolidine-2,4-dione

ChemComp-SR4:
2,3-dihydro-1-benzoxepine-5-carboxylic acid

ChemComp-SRJ:
(3~{S})-2-(cyclopropylmethyl)-3-[(~{S})-oxidanyl(phenyl)methyl]-2-azabicyclo[2.2.2]octan-4-ol

ChemComp-A7K:
[2-[4-(hydroxymethyl)piperidin-1-yl]phenyl]methylazanium

ChemComp-JFS:
[4-(1H-benzimidazol-1-yl)phenyl]methanol

ChemComp-54F:
3-(pyridin-2-yloxy)aniline / 3-(2-ピリジルオキシ)アニリン

ChemComp-SFY:
4-amino-N-(pyridin-2-yl)benzenesulfonamide / スルファピリジン / 薬剤, 抗生剤*YM

ChemComp-LVD:
1-phenylmethoxyurea / N-(ベンジルオキシ)尿素

ChemComp-K3D:
4-acetyl-N-ethylpiperazine-1-carboxamide

ChemComp-A9B:
5-(4-chlorophenyl)furan-2-carbohydrazide

ChemComp-6T5:
6-methyl-5-[(4-propan-2-ylphenyl)amino]-2~{H}-1,2,4-triazin-3-one

ChemComp-JMM:
[4-(cyclopropanecarbonyl)piperazin-1-yl](furan-2-yl)methanone

ChemComp-SSY:
~{N}-(3-ethanoylphenyl)-2,2,2-tris(fluoranyl)ethanamide

ChemComp-STV:
~{N}-(1,3-benzodioxol-5-ylmethyl)ethanesulfonamide

ChemComp-NZ4:
N-(3-acetylphenyl)morpholine-4-carboxamide

ChemComp-AYS:
2-[(4-chlorophenyl)amino]benzamide

ChemComp-PO6:
2-phenoxyacetamide / フェノキシアセトアミド

ChemComp-SV4:
1-(3-methylpyridin-2-yl)-1,4-diazepane

ChemComp-SVD:
(5~{R})-5-~{tert}-butyl-2-methyl-1-oxidanyl-pyrazolidin-3-one

ChemComp-SVG:
(~{E})-1-(4-chlorophenyl)-~{N}-(pyridin-3-ylmethyl)ethanimine

ChemComp-SVJ:
(1~{S},5~{R})-8-methyl-8-azabicyclo[3.2.1]octan-3-amine / (1R,5S)-トロパン-3α-アミン

ChemComp-SVM:
1-[(1~{R},2~{R},4~{S})-2-bicyclo[2.2.1]heptanyl]-3-(2-pyridin-2-ylethyl)thiourea

ChemComp-SW7:
4-methylbenzamide / 4-メチルベンズアミド

ChemComp-2O6:
5-(trifluoromethyl)-1,2-benzoxazol-3-amine

ChemComp-SWD:
4-chloranylthieno[3,2-d]pyrimidine / 4-クロロチエノ[3,2-d]ピリミジン

ChemComp-LO5:
1-(1,3-benzodioxol-5-yl)-~{N}-[[(2~{R})-oxolan-2-yl]methyl]methanamine

ChemComp-JGG:
N-[(4-cyanophenyl)methyl]morpholine-4-carboxamide

ChemComp-LO8:
(2~{S})-2-methyl-4-(oxetan-3-yl)-~{N}-(phenylmethyl)piperazine-2-carboxamide

ChemComp-LOE:
1-[[(3~{S})-1,4-dioxaspiro[4.5]decan-3-yl]methyl]piperidine

ChemComp-LOK:
methyl ~{N}-[3-(methoxycarbonylamino)phenyl]carbamate / m-フェニレンビス(カルバミド酸メチル)

ChemComp-LOQ:
1-(4-methylphenyl)pyrrolidine-2,5-dione / N-(4-メチルフェニル)スクシンイミド

ChemComp-LPZ:
2-(4-methylphenoxy)-1-(4-methylpiperazin-4-ium-1-yl)ethanone

ChemComp-SB4:
4-(4-FLUOROPHENYL)-1-(4-PIPERIDINYL)-5-(2-AMINO-4-PYRIMIDINYL)-IMIDAZOLE / 4-[1-(ピペリジン-4-イル)-4-(4-フルオロフェニル)-5-イミダゾリル]ピリミジン-2-アミン

ChemComp-CA:
Unknown entry / カルシウムジカチオン

ChemComp-LOT:
6-[2,5-bis(oxidanylidene)pyrrolidin-1-yl]pyridine-3-sulfonamide

ChemComp-LOW:
(5~{S},7~{R})-3-azanyladamantan-1-ol / 3-アミノアダマンタン-1-オ-ル

ChemComp-OFW:
(2~{R})-~{N}-[(2-azanyl-2-adamantyl)methyl]-4-[6-[2,5-bis(oxidanylidene)pyrrolidin-1-yl]pyridin-3-yl]sulfonyl-2-methyl-morpholine-2-carboxamide

ChemComp-OFQ:
(2-azanyl-2-adamantyl)methanol

ChemComp-OFZ:
1-(2-adamantylmethyl)-3-ethyl-guanidine

ChemComp-OG5:
(3~{R})-~{N}-[(2-azanyl-2-adamantyl)methyl]-3-[[6-[2,5-bis(oxidanylidene)pyrrolidin-1-yl]pyridin-3-yl]sulfonylamino]-3-phenyl-propanamide

ChemComp-OKZ:
4-[2,5-bis(oxidanylidene)pyrrol-1-yl]-~{N}-propyl-benzenesulfonamide

ChemComp-OL8:
~{N}-[3-[2,5-bis(oxidanylidene)pyrrol-1-yl]phenyl]furan-2-carboxamide

由来
  • homo sapiens (ヒト)
  • mus musculus (ハツカネズミ)
キーワードSIGNALING PROTEIN / IL-1 BETA / SGC - Diamond I04-1 fragment screening / PanDDA / XChemExplorer / TRANSFERASE / P38 / MAPK14 / KINASE / FBDD / Fragment Based Drug Design / Transferase.

+
万見文献について

-
お知らせ

-
2022年2月9日: EMDBエントリの付随情報ファイルのフォーマットが新しくなりました

EMDBエントリの付随情報ファイルのフォーマットが新しくなりました

  • EMDBのヘッダファイルのバージョン3が、公式のフォーマットとなりました。
  • これまでは公式だったバージョン1.9は、アーカイブから削除されます。

関連情報:EMDBヘッダ

外部リンク:wwPDBはEMDBデータモデルのバージョン3へ移行します

-
2020年8月12日: 新型コロナ情報

新型コロナ情報

URL: https://pdbjlvh1.pdbj.org/emnavi/covid19.php

新ページ: EM Navigatorに新型コロナウイルスの特設ページを開設しました。

関連情報:Covid-19情報 / 2020年3月5日: 新型コロナウイルスの構造データ

+
2020年3月5日: 新型コロナウイルスの構造データ

新型コロナウイルスの構造データ

関連情報:万見生物種 / 2020年8月12日: 新型コロナ情報

外部リンク:COVID-19特集ページ - PDBj / 今月の分子2020年2月：コロナウイルスプロテーアーゼ

+
2019年1月31日: EMDBのIDの桁数の変更

EMDBのIDの桁数の変更

  • EMDBエントリに付与されているアクセスコード(EMDB-ID)は4桁の数字(例、EMD-1234)でしたが、間もなく枯渇します。これまでの4桁のID番号は4桁のまま変更されませんが、4桁の数字を使い切った後に発行されるIDは5桁以上の数字(例、EMD-12345)になります。5桁のIDは2019年の春頃から発行される見通しです。
  • EM Navigator/万見では、接頭語「EMD-」は省略されています。

関連情報:Q: 「EMD」とは何ですか？ / 万見/EM NavigatorにおけるID/アクセスコードの表記

外部リンク:EMDB Accession Codes are Changing Soon! / PDBjへお問い合わせ

+
2017年7月12日: PDB大規模アップデート

PDB大規模アップデート

  • 新バージョンのPDBx/mmCIF辞書形式に基づくデータがリリースされました。
  • 今回の更新はバージョン番号が4から5になる大規模なもので、全エントリデータの書き換えが行われる「Remediation」というアップデートに該当します。
  • このバージョンアップで、電子顕微鏡の実験手法に関する多くの項目の書式が改定されました(例：em_softwareなど)。
  • EM NavigatorとYorodumiでも、この改定に基づいた表示内容になります。

外部リンク:wwPDB Remediation / OneDepデータ基準に準拠した、より強化された内容のモデル構造ファイルが、PDBアーカイブで公開されました。

-
万見文献

EMDB/PDB/SASBDBから引用されている文献のデータベース

  • EMDB/PDB/SASBDBのエントリから引用されている文献のデータベースです
  • Pubmedのデータを利用しています

関連情報:EMDB / PDB / SASBDB / 万見 (Yorodumi) / EMN文献 / 新しいEM Navigatorと万見の変更点

他の情報も見る